A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
A Randomized, Open Label, Multicenter, Parallel-group, Positive-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid.
This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Chunmiao Li
- Phone Number: 18321232774
- Email: chunmiao.li@innoventbio.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Shanghai Fudan University HuaShan Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Participants must be aged between 18 and 75 years old (inclusive, as of the time of signing the informed consent form), with no gender restrictions;
- Body Mass Index (BMI) should fall within the range of 18.0 to 40.0 kg/m² (including both ends of the range);
- Subjects must meet the 2015 ACR/EULAR classification criteria for the diagnosis of gout (refer to Appendix 4);
- At the screening stage, subjects must have a blood uric acid level of ≥480 μmol/L;
- Subjects must voluntarily sign the informed consent form and agree to strictly adhere to the requirements outlined in this protocol.
Exclusion criteria (brief):
- History of allergy to any component of Tigulixostat;
- Previous allergy or intolerance to Febuxostat;
- Subjects who have taken uric acid lowering medications within 2 weeks prior to screening;
- Subjects who experienced an acute gout flare-up within 4 weeks prior to screening or immediately before the first dose administration;
- Subjects considered to have secondary gout (elevated serum uric acid due to causes other than renal insufficiency);
- Subjects with a history of xanthinuria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Febuxostat 40mg
Tablets, Once a day (QD), Per oral
|
Tablets, Once a day (QD), Per oral
|
|
Experimental: IBI128 50mg
Tablets, Once a day (QD), Per oral
|
Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
|
|
Experimental: IBI128 200mg
Tablets, Once a day (QD), Per oral
|
Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
|
|
Experimental: IBI128 100mg
Tablets, Once a day (QD), Per oral
|
Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The proportion of subjects in each treatment group with serum uric acid levels <360 μmol/L after continuous treatment for 16 weeks
Time Frame: Week 16
|
Week 16
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of subjects in each treatment group with serum uric acid levels <300 μmol/L after continuous treatment for 16 weeks
Time Frame: Week 16
|
Week 16
|
|
|
The proportion of subjects in each treatment group with serum uric acid levels <360, <300 μmol/L after continuous treatment for 2, 4, 8, 12 weeks
Time Frame: Week 2, 4, 8, 12
|
Week 2, 4, 8, 12
|
|
|
Absolute and percentage Changes in serum uric acid levels from baseline in subjects of each treatment group after continuous treatment for 2, 4, 8, 12, and 16 weeks
Time Frame: Baseline, Week 2, 4, 8, 12
|
Baseline, Week 2, 4, 8, 12
|
|
|
The proportion of subjects experiencing gout flares and the number of gout flare occurrences within every 4 weeks from the first dose, among those receiving various doses of Tigulixostat tablets and Febuxostat tablets
Time Frame: Baseline through Week 16/18
|
Baseline through Week 16/18
|
|
|
Number of subjects with Adverse Event, Serious Adverse Events, Treatment Emergent Adverse Event, Adverse event of special interest
Time Frame: Baseline through Week 18/20
|
Baseline through Week 18/20
|
|
|
Number of subjects with clinically significant changes in physical examination results
Time Frame: Baseline through Week 16/18
|
Clinically significant abnormal physical examination findings reported by the investigator.
|
Baseline through Week 16/18
|
|
Number of subjects with clinically significant changes in in vital sign
Time Frame: Baseline through Week 16/18
|
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure.
|
Baseline through Week 16/18
|
|
Number of subjects with clinically significant changes in clinical laboratory parameters
Time Frame: Baseline through Week 16/18
|
Clinical laboratory parameters including white blood cell, red blood cell, hemoglobin, platelet, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, serum creatinine, fasting serum glucose, toal bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, alkaline phosphatase, serum potassium, creatine phosphokinase, hs-CRP, prothrombin time, thrombin time, activated partial thromboplastin time, international normalized ratio
|
Baseline through Week 16/18
|
|
Number of subjects with clinically significant changes in electrodiagram
Time Frame: Baseline through Week 16/18
|
Electrodiagram parameters including PRinterval, heart rate, RRinterval, corrected QT interval by Fridericia's formula
|
Baseline through Week 16/18
|
|
Plasma concentration of Tigulixostat
Time Frame: Baseline through Week 16/18
|
Baseline through Week 16/18
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIBI128A201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.